According to the survey analysis, one of the eight adults in the US has taken drugs like ozemic.
But over 30% According to a study by US healthcare data company Blue Health Intelligence, before making a meaningful effect on the health of the drug, only four weeks after the meds drops the meds after four weeks.
With weight loss, ozmpic, which is so old under the brand name vegovi, is followed by a reputation for its unpleasant side effects. The most common side effects people have nausea, diarrhea or other digestive problems in the report.
Vision changes, erectile dysfunction and changes in mood have been reported, and you may have side effects such as ʺozepic faceʺ or ozozepic butt (relaxation in all wrong locations).
But whether worrying medical professionals are more concerned that there are reports of serious medical diseases after weight loss, ie for several months, it is called semaglutide or GLP -1 drugs.
The most side effects about side effects include effects on pancreatitis and musculoskeletal disorder, ʺ Penny Ward, King’s College London, a doctor at London, UK, told DW.
A regulator in the UK has exposed the potentially malignant side effects of acute pancreatitis -at least ten deaths after an inflammation of the thorny were linked to this condition among the British users of GLP -1 drugs.
Side effects ‘not unusual’ after clinical trials
GLP-1 drugs have been in the US market since 2017. Ozempic was first approved to treat type 2 diabetes, while Wegovy was approved in 2021 as a weightless medicine.
Clinical trials tested their safety and effectiveness, showing them safely for their intended users. But since the release of the public, people have reported new side effects with people that did not appear in the original clinical trials.
The ward stated that it is not uncommon for additional adverse reactions after a product clinical use.
ʺ Rarer side effects may emerge because more patients take thesis medications in clinical practice, ʺ he said, “Just as a result of people of a larger number of people involved in clinical development tests.
ʺ Why is it that we continue to monitor the safety of medicines on the market. The ward said.
One major study Published in the journal Nature therapy In January 2025, it has been prescribed to systematically analyze all the reports of all reported health risks of more than 215,000 people to take GLP-1 drugs for the treatment of diabetes.
Researchers found the risks of taking GLP -1 drugs beyond already recognized people in clinical tests, including 11% increased risk in arthritis and 146% increase of pancreatitis. Therefore, the risk of low blood pressure, dizziness or fainting, kidney stones and kidney inflammation increased.
The study highlighted the famous risks of several gastrointestinal disorders, supporting several previous studies, with increasing risk of gastrointestinal side effects.
More research on side effects needs
Last year, people started reporting that they became blind after taking Vagovi. Researchers investigating the case found that GLP-1 drugs are associated with the risk of the optic nerve affecting the optic nerve, which is called nonsetric anterior ischemic optic neuropathy (Naion).
While the situation is rare, the estimated 10 in 100,000 people affects 10, A Study published in journal Jama ophthalology It was found that people with diabetes taking GLP-1 drugs are four times the possibility of developing Naion compared to the population average.
ʺ This research suggests a relationship between semaglutide treatment and a form of vision optic neuropathy, but it will ideally be tested in large studies, ʺ Graham McGown, Queen’s University Belfast, for the honorary professors of physiology in the UK.
Experts say that GLP-1 requires a lot of research in the representative population to better understand the side effects of GLP-1 and to better understand their real world risks.
For example, [more data is needed about] Those taking drugs for obesity, who require more doses than people with diabetes, and carry it for more than two years, of Karolina Skibika, a neuroendocrinologist at the University of Calgary, Canada.
ʺ But specific, we need studies that include. Women show unique side-effects for many pharmacotherapy, and still [in] In most studies, women are often reduced to various stalls of testing, the OCK Skibica said.
Benefits are ahead of risks
Despite concerns about the new side effects, Skibika told DW, of the list of benefits for this drug, if taken as a presscrade, is still longer and more effective than the risk. It promises to save and improve many lives.
Thus, Skibika stated that it was elunlikely that that the presence of rare but serious side effects would be ground to create new, strict recommendations to determine GLP drugs.
Researchers are also getting amazing ‘beneficial’ side effects for taking GLP -1 dug.
Studies show that the use of GLP-1 drug is associated with low risk of dementia and Alzheimer’s disease. Therefore researchers are investigating whether drugs can be used to treat substance use disorders.
The January study led to reducing the risks of blood coagulation and clotting disorders, cardiral and metabolic disorders and reduced many respiratory conditions in patients with GLP -1 drugs.
The author guesses that GLP-1 drugs can affect the risk of human condition for two reasons: first because they act on many parts of the body, and second because they treat, which contributes to many health issues.
Edited by: Christie Pladson
